Releases New Report on the Varicella Attenuated Live Vaccine Market 2021-2025 | Global Key Players - GSK, Merck, BCHT, Shanghai Institute, Keygen, Green Cross, Biken
Overview of Global Varicella Attenuated Live Vaccine Market:
This report studies the Global Varicella Attenuated Live Vaccine Market over the forecast period of 2020 to 2025. The Global Varicella Attenuated Live Vaccine Market is expected to grow at an impressive Compound Annual Growth Rate (CAGR) from 2020 to 2025.
According to the market research study, Varicella zoster is also known as Human alphaherpesvirus 3 and causes chicken pox and herpes zoster in humans. Chicken pox is highly contagious and is usually spread by direct contact or through air by coughing and sneezing. The illness usually causes an itchy rash and leads to the formation of over 400 blisters all over the body. In addition, it causes headache, fussiness, and coughing in the patients.
Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/291420 .
The most important key factors driving the growth of the Global Varicella Attenuated Live Vaccine Market are surge in immunization programs across the world, rapid growth in awareness related to the use of varicella live vaccines and rise in adoption of varicella vaccination globally.
The Global Varicella Attenuated Live Vaccine Market is segmented on the basis of Type, Application and Region. Based on the Type, the Global Varicella Attenuated Live Vaccine Market is sub-segmented into Monovalent Vaccine, Combination Vaccine and others. On the basis of Application, the Global Varicella Attenuated Live Vaccine Market is classified into Kids Injection, Adults Injection and others.
In terms of the geographic analysis, North America accounted for the major share of the Varicella Attenuated Live Vaccine Market in 2018 and is expected to continue this trend owing to easy availability of varicella live vaccines, presence of skilled healthcare experts, and presence of major key players that offer Varicella Attenuated Live Vaccine. APAC is expected to grow at the fastest rate during the forecast period due to surge in awareness related to importance of immunization and rise in disposable income.
Global Varicella Attenuated Live Vaccine Market Objectives:
1 To provide detailed information regarding key factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the Varicella Attenuated Live Vaccine Market
2 To analyze and forecast the size of the Varicella Attenuated Live Vaccine Market, in terms of value and volume
3 To analyze opportunities in the Varicella Attenuated Live Vaccine Market for stakeholders and provide a competitive landscape of the market
4 To define, segment, and estimate the Varicella Attenuated Live Vaccine Market based on deposit type and end-use industry
5 To strategically profile key players and comprehensively analyze their market shares and core competencies
6 To strategically analyze micromarkets with respect to individual growth trends, prospects, and contribution to the total market
7 To forecast the size of market segments, in terms of value, with respect to main regions, namely, Asia Pacific, North America, Europe, the Middle East & Africa, and South America
8 To track and analyze competitive developments, such as new product developments, acquisitions, expansions, partnerships, and collaborations in the Varicella Attenuated Live Vaccine Market
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Varicella Attenuated Live Vaccine Market Report 2021” @ https://www.businessindustryreports.com/buy-now/291420/single .
Top Leading Key Manufacturers are: Merck, BCHT, Shanghai Institute, GSK, Keygen, Green Cross, Biken, Shanghai Rongsheng Biotech, Changchun Changsheng Life Sciences Limited and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.
Latest Medical Industry News:
GlaxoSmithKline plc (GSK) (March 26, 2021) - GSK receives CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis - GlaxoSmithKline plc (GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN). The CHMP opinion is one of the final steps in the marketing authorisation procedure prior to approval by the European Commission. If approved, Benlysta would become the first and only biologic approved for both Systemic Lupus Erythematosus (SLE) and LN in the European Union. This CHMP opinion follows the recent label expansion by the US Food and Drug Administration to include LN.
Christopher Corsico, Senior Vice President, Development, GSK, said: “Active lupus nephritis occurs in more than 1 million patients with systemic lupus erythematosus worldwide. It causes inflammation in the kidneys and can lead to end-stage kidney disease which may require dialysis or a transplant. The CHMP’s positive opinion brings us one step closer to providing physicians and patients in Europe with the first treatment option specifically designed to work in lupus and lupus nephritis.”
The CHMP opinion is based on data from the BLISS-LN (Efficacy and Safety of Belimumab in Adult Patients with Active Lupus Nephritis) study and the unmet need in this patient population. The BLISS-LN study is the largest and longest phase 3 study conducted in active LN, involving 448 adult patients. The study met its primary endpoint demonstrating that a statistically significant greater number of patients achieved Primary Efficacy Renal Response at two years (or 104 weeks) when treated with belimumab plus standard therapy compared to placebo plus standard therapy in adults with active LN (43% vs 32%, odds ratio (95% CI) 1.55 (1.04, 2.32), p=0.0311). Statistical significance compared to placebo across all four major secondary endpoints was achieved, including Complete Renal Response at Week 104 and Time to Renal-Related Event or Death. The adverse reactions observed in BLISS-LN were consistent with the known safety profile of Benlysta administered intravenously plus standard therapy in patients with SLE.
Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Varicella Attenuated Live Vaccine in these regions, from 2013 to 2025 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America
Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/291420 .
Major Points in Table of Contents:
Global Varicella Attenuated Live Vaccine Market Report 2021
1 Varicella Attenuated Live Vaccine Product Definition
2 Global Varicella Attenuated Live Vaccine Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Varicella Attenuated Live Vaccine Shipments
2.2 Global Manufacturer Varicella Attenuated Live Vaccine Business Revenue
2.3 Global Varicella Attenuated Live Vaccine Market Overview
2.4 COVID-19 Impact on Varicella Attenuated Live Vaccine Industry
3 Manufacturer Varicella Attenuated Live Vaccine Business Introduction
3.1 Merck Varicella Attenuated Live Vaccine Business Introduction
3.2 BCHT Varicella Attenuated Live Vaccine Business Introduction
3.3 Shanghai Institute Varicella Attenuated Live Vaccine Business Introduction
3.4 GSK Varicella Attenuated Live Vaccine Business Introduction
3.5 Keygen Varicella Attenuated Live Vaccine Business Introduction
3.6 Green Cross Varicella Attenuated Live Vaccine Business Introduction
………………. Request free sample to get a complete Table of Content
BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that hold the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.
Business Industry Reports
Pune – India
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Releases New Report on the Varicella Attenuated Live Vaccine Market 2021-2025 | Global Key Players - GSK, Merck, BCHT, Shanghai Institute, Keygen, Green Cross, Biken here
News-ID: 2262665 • Views: 361
More Releases from Business Industry Reports
Tetracaine Market Exhibits a Lucrative Growth Potential during 2021-2025 | Endo …
BusinessIndustryReports has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Tetracaine Market” Research Report 2021 provides an in-depth analysis of the Tetracaine with the forecast of market size and growth. The analysis includes addressable market, market by volume, market share by business type and by segment (external and in-house). The research study examines the Tetracaine on the basis of a number of criteria,
Cyber Warfare Market Evenly Poised To Reach A Market Value of US$ By Share, Size …
Overview of Global Cyber Warfare Market: This report provides in-depth study of “Global Cyber Warfare Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cyber Warfare Market report also provides an in-depth survey of key players in the market organization. According to the market research study, the Cyber Warfare is virtual conflict between state, organization, or country by the use of computer technology to disrupt activities
Covid-19 Impact on Cranio Maxillofacial Implant Market 2021-2025: Business Growt …
Overview of Global Cranio Maxillofacial Implant Market: This report provides in-depth study of “Global Cranio Maxillofacial Implant Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cranio Maxillofacial Implant Market report also provides an in-depth survey of key players in the market organization. According to the market research study, Craniomaxillofacial Implants are medical implants used in surgeries of maxillofacial region such as, head, face, neck, oral,
Beginning of the bloom: The Rise of the Biohacking Market 2021-2025 | Global Key …
Global Biohacking Market Synopsis: The report covers a forecast and an analysis of the Biohacking Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Biohacking Market along with the impact they have on the demand over the forecast
More Releases for Vaccine
Influenza Vaccine Market | DPIResearch.com
According to the DPI Research new growth forecast report titled “Worldwide Influenza Vaccines Market Size | Forecast to 2027” to Witness Comprehensive Growth by 2027 DPI Research published a new report on Worldwide Influenza Vaccines Market. The research offers an extensive analysis of key players active in the Worldwide Influenza Vaccines Market. Detailed analysis on operating business segments, product portfolio, business performance, and key strategic developments is offered in the research.
Tetanus Toxoid Vaccine Market
The report for Global Tetanus Toxoid Vaccine Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. Market Highlights: Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. The spasms may be very severe and even cause bone
Key Tools for Innovative Vaccine Designs: Vaccine Adjuvants
The report “NORTH AMERICA VACCINE ADJUVANTS MARKET” provides the detail description of market segmentation, applications, growth, size, and outlook. The market is projected to reach USD $278 Million by 2024, at a CAGR of 11.3%. An adjuvant is an immunological agent, which modifies the effect of other agents. Adjuvants can also act as an irritant, which engages and amplifies the body immune response. Adjuvants are added to vaccines to boost the
Vaccine Market Demand is Increasing
U.S. Vaccine Market: Snapshot The overall vaccine industry has strengthened itself in terms of its growth rate, with a relatively higher growth rate than most other healthcare market segments. Vaccination has been an invaluable addition to better public health, and has helped millions of children, adults and animals from deadly diseases. The CDC stated in a report that diseases such as diphtheria, polio, and smallpox have been fully eliminated, while measles,
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Peanut Allergy Vaccine Market
Allergies are medical conditions caused primarily by hypersensitivity of the immune system to some external stimulus. Allergy may cause anaphylaxis—a medical condition that can cause irritation of the skin, swelling of throat, shortness of breath, and in some cases, death. Allergies are caused by various allergens such as pollen grains, or certain foods such as peanuts. Vaccination is the process of administering antigenic material or a vaccine to stimulate one’s